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Introduction: Prolidase deficiency (PD) is a rare autosomal recessive disorder which may have a wide spectrum of
clinical features. These features include a characteristic facies, cognitive impairment, rashes or skin ulceration,
splenomegaly, recurrent infections involving mainly the respiratory system, and iminodipeptiduria. The disorder is
caused by a mutation in the PEPD gene.
Objective: To describe a cohort of unrelated PD patients from Northern Israel whose inborn error of metabolism
was associated with systemic lupus erythematosus (SLE) and to identify in the medical literature all PD cases
mimicked by and/or associated with SLE.
Methods: Three patients with PD associated with SLE were clinically, biochemically and genetically investigated.
These patients were from 3 unrelated consanguineous families residing in Northern Israel. A computer-assisted
(PubMed) search of the medical literature from 1975 to 2011 was performed using the following key words:
Prolidase deficiency, SLE, and systemic lupus erythematosus.
Results: An association between PD and SLE was found in 10 PD patients. These 10 patients included three from
our cohort of 23 PD patients, and seven out of just under 70 PD patients previously reported in the literature.
Conclusion: The present findings underscore the relatively high incidence of the association between SLE and PD,
suggesting that this association may not be coincidental. The phenotypic similarities between SLE and PD might
suggest that the PEPD gene constitutes a modifier gene or a genetic risk factor in the causation of SLE.Background
Prolidase deficiency (PD) (McKusick 170100) is a rare
recessive disorder with an estimated incidence of 1–2 per
1 million births [1]. Prolidase, a ubiquitously distributed
dipeptidase, is involved in the latter stages of degradation
of endogenous and dietary proteins. It is particularly
important in collagen catabolism by affecting the hydrolysis
of proline- or hydroxyproline-containing dipeptides at
the C-terminal position. The phenotypic expression of
PD is highly variable and typically includes mental re-
tardation, recurrent respiratory infections, splenomegaly
and dysmorphic facies. A major feature is chronic* Correspondence: yonatanbutbul@gmail.com
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distribution, and reproduction in any mediumintractable ulceration of the skin, particularly on the
lower limbs. Although the age of onset of the disease
varies from birth to 22 years of age, some cases remain
asymptomatic [1,2].
Deficiency of prolidase activity leads to massive imido-
peptiduria. Various diagnostic techniques have been
developed for the detection of imidodipeptides in the
urine. However, confirmation of the diagnosis requires
the measurement of prolidase activity in erythrocytes,
leukocytes or fibroblasts in culture and/or sequence analysis
of the PEPD gene [1].
SLE is a multi-system autoimmune disease characterized
by widespread inflammation of blood vessels and con-
nective tissues. It has very variable clinical manifestations
and specific autoantibodies. The estimated prevalence of
SLE in adults is 12–50 per 100,000 individuals [3,4].ntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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of 16 years. Onset of SLE is rare before 5 years of age.
Pediatric SLE usually results in more aggressive disease
and a poorer prognosis [5,6].
An association between prolidase deficiency and systemic
lupus erythematosus has been previously reported in the
literature [7-10]. Both prolidase deficiency and SLE are
associated with disturbances in immune function and have
many clinical features in common. It is quite possible that
prolidase deficiency is a risk factor for development of SLE.
The results of our study underscore the relatively high
incidence of the association between SLE and PD and
support that this association is not coincidental.Case series
Patient 1
A 4.5 year-old Druze boy, of consanguineous healthy
parents, was referred for evaluation of vasculitic skin
lesions over his hands, feet, fingertips and earlobes.
These lesions had started six months prior to admission.
His seven year old brother is healthy. One distant rela-
tive was diagnosed with SLE at the age of 28.
At the age of two, a purple rash appeared on the back
of his hands, on the tip of all his fingers and his ear
lobes. There was no history of fever, arthritis, alopecia,
oral lesions, or respiratory or gastrointestinal symptoms.
On admission, he appeared well. He had dysmorphic
facial features. Vasculitic lesions were observed on the
back of his hands, ear lobes, feet and fingertips
(Figure 1a -1b). The rest of the physical examination was
normal.
Laboratory findings: Hemoglobin concentration was
12 g/dl, white blood cell count 12,000/μL, platelets
113 × 103/μL, and Westergren erythrocyte sedimentation
rate (ESR) 45 mm/h. The CRP was normal. There was
mild elevation of liver enzymes. The urinalysis, serumFigure 1 Clinical and histopathological findings of patient 1:
a: well demarcated edematous plaques on the dorsal side of
the fingers. b: scaly plaques with central atrophy on both
earlobes clinically compatible with Discoid Lupus
Erythematosus.electrolytes, urea, creatinine, creatine kinase, albumin
and bilirubin concentration tests were normal.
An immunological evaluation revealed a high serum
concentrations of IgG2 (960 mg/dl) IgA (667 mg/dl),and
a normal level of IgM. Antinuclear antibodies (ANA)
were positive at a titer of 1:640 (homogenous pattern).
The antibodies to double-stranded DNA, Anti-RNP,
anti-SM, Anti Ro (SS-A) and Anti La (SS-B) were also
elevated. Complement levels of C3 and C4 were low.
Antibodies to cardiolipin, SCL-70, PM-1, and centro-
mere were negative. A skin biopsy was compatible with
hypertrophic discoid lupus (Figure 2).
Urinary amino acid analysis revealed hyperiminodipep-
tiduria, which was suggestive of PD. The diagnosis of PD
was confirmed by mutation analysis of the PEPD gene,
revealing the S202F missense mutation which was previ-
ously found to be common among the Druze with PD in
Northern Israel and the Golan Heights (10). Treatment
consisted of oral prednisone 1 mg/kg/d and hydroxy-
chloroquine 6 mg/kg/d. The child improved well on
treatment, except for the discoid skin lesions. At the age
of 4.5 years he presented with proteinuria and mild
hematuria. A renal biopsy was performed and demon-
strated glomerular changes consistent with WHO Class
IV Lupus nephritis. High dose prednisone was begun at
a dose of 2 mg/kg as well as mycophenolate mofetil at a
dose of 1200 mg/m² with gradual improvement.Figure 2 Histopathology of the involved skin from the dorsal
aspects of a finger showing typical changes of cutaneous
Lupus Erythematosus including vacuolar degeneration of the
basal- cell layer, and focal thickening of the basement
membrane (hematoxylin and eosin, x100).
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A 16-year-old Moslem Arab girl, the second of three
healthy children, born to consanguineous healthy parents,
was admitted to the hospital at the age of 5 yrs with a
lobar pneumonia. There was no family history suggestive
of PD. She was hospitalized at the age of 1 month because
of a diffuse skin rash and failure to gain weight, which was
attributed to milk allergy. A skin biopsy was compatible
with seborrheic dermatitis. Local steroid cream applica-
tions and hypoallergenic formula feeding were instituted,
with an apparent good response. She was admitted again
at three months of age with bacterial pneumonia. Evalu-
ation for underlying immunodeficiency syndrome and cys-
tic fibrosis was negative. During the following years the
child exhibited mild developmental delay. Splenomegaly
was detected as an outpatient.
On her third admission under 1 year of age, the pa-
tient looked thin and dysmorphic (Figure 3). She had
microcephaly, a prominent metopic suture, clinodactaly
and brachydactyly. There were no skin lesions. The heart
and lung examinations were normal. A soft spleen was
palpated 6 cm below the left costal margin; the liver was
not enlarged. The rest of the physical examination was
normal.
Laboratory findings at that time: Hemoglobin concen-
tration of 9 g/dl, white blood cell count 5.1 × 103/μL,
and platelets 171 × 103/μL. The following tests wereFigure 3 Patient no. 2 depicting the characteristic facial
dysmorphism of PD.within normal limits: urinalysis, Westergren erythrocyte
sedimentation rate (ESR), serum electrolytes, urea,
creatinine, creatine kinase, albumin, and liver function
tests. Bone marrow aspiration and a gallium scan were
also normal. In view of the patient’s dysmorphic features
and past clinical history, she underwent a metabolic
work-up. The results were consistent with the diagnosis
of PD. The diagnosis of PD was confirmed by mutation
analysis of the PEPD gene which revealed the A212P
missense mutation in exon 2 [10]. The patient was treated
with antibiotics and was subsequently followed up by our
Metabolic Unit.
Three years later the patient was admitted following
seven days of fever, with left lower lobe pneumonia,
macroscopic hematuria and proteinuria. Laboratory
evaluation demonstrated acute renal failure, pancyto-
penia and hypoalbuminemia. Immunological studies
showed a highly positive antinuclear antibodies assay
(ANA), and a positive double stranded DNA titer. There
were low levels of C3 and C4. Anti-Ro/SS-A anti La/SS-B,
anti-RNP, anti-SM and anti-cardiolipin antibodies were
negative by immunodiffusion. A direct Coombs test was
positive. A renal biopsy was performed and demonstrated
glomerular changes consistent with WHO Class IV Lupus
nephritis. Following diagnosis of SLE, treatment with
pulse methylprednisolone and pulse cyclophosphamide
was begun. Nevertheless, the patient's renal function
deteriorated rapidly; she became anuric and required
hemodialysis. With continuing medication and dialysis
over five months, the renal function improved, and the
patient could gradually be weaned off hemodialysis,
although massive proteinuria persisted. A few months
later she presented with a focal seizure on her left side
and hypertension. She underwent further evaluation in-
cluding MRI of the brain which showed multiple bilateral
subcortical white matter lesions mainly over the parie-
tooccipital area with leptomeningeal enhancement. Her
lumbar puncture results were normal. The findings were
consistent with CNS vasculitis. The patient was treated
with pulse methylprednisolone and continued therapy
with pulse cyclophosphamide. Her seizures stopped and
she recovered completely. Eventually, end-stage renal fail-
ure developed in spite of therapy with high dose steroids,
cyclophosphamide, azathioprine, and anti-hypertensive
drugs. The patient has recently undergone successful renal
transplantation. Her lupus disease has been inactive for
the last year on only a low dose of daily steroids.
Patient 3
A 24-year-old Druze female is the seventh child of 1st
degree consanguineous, healthy Parents. Her paternal
uncle was diagnosed with PD and died of severe lung
disease a few years prior to this patient’s first admission.
She had been followed in another hospital since birth.
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recurrent episodes of bacterial pneumonia. Over the
years she also developed severe clubbing of the fingers,
bronchiectasis, a non-specific maculopapular rash of the
skin, splenomegaly, and pancytopenia. At 12 years of age
she was referred to our hospital for further evaluation.
On admission, her characteristic dysmorphic features
(Figure 4) reminded us of our previous patient with pro-
lidase deficiency. The diagnosis of PD in this patient was
confirmed by metabolic enzymatic studies and by muta-
tion analysis of the PEPD gene which revealed the S202F
missense mutation similar to the first patient [10]. In
addition, a diagnosis of concurrent SLE was made on
the basis of the following hematological and immuno-
logical studies: thrombocytopenia, positive Coombs test,
positive ANA, positive dsDNA and low C3 and C4.
Other antibodies titers including anti-cardiolipin and
lupus anti- coagulants were also positive. Anti Ro/SS-A,
anti La/SS-B, anti Sm were negative. The urine analysis
was repeatedly normal.
The patient was treated for severe thrombocytopenia
with high dose steroids, IV- immunoglobulin, and cyclo-
phosphamide. Yet she continued to have thrombocyto-
penia, thus necessitating splenectomy. The hematological
and immunological manifestations of SLE resolved nine
months after she had the splenectomy. Currently, twelve
years after the initial diagnosis of SLE, the patient is on
low dose prednisone maintenance therapy mainly for mildFigure 4 Patient no. 3 with milder dysmorphic features.arthritis and progressive lung disease. CT imaging of the
chest demonstrated mainly cystic lung lesions and ground
glass opacity. Recently she experienced further deterior-
ation in her pulmonary function and secondary pulmonary
hypertension. At present she is oxygen dependent.
Discussion
Prolidase deficiency (PD) (OMIM 170100) is a rare disease
with an estimated incidence of 1–2 cases per million
births. This disease is probably underdiagnosed. (1). This
autosomal recessive, pan-ethnic disorder is characterized
by a highly variable phenotype including, rashes or skin
ulceration, dysmorphic features, cognitive impairment,
anemia, splenomegaly, and recurrent infections. Fewer
than 70 PD patients have been documented in the medical
literature, 10 of them were reported to have SLE features.
Twenty-three patients with PD are currently followed in
our institution of which only the above 3 patients have
developed SLE (13%), This association is much higher
than the association of SLE in the normal population.
The prolidase enzyme hydrolyzes dipeptides that have
either carboxy-terminal proline or Hydroxyproline. Pro-
lidase has a major role in the recycling of proline
released during the degradation of collagen and dietary
proteins [11]. Although there is considerable knowledge
concerning the putative roles of the prolidase enzyme
[12], the pathophysiology of PD remains an enigma.
Prolidase is particularly important in collagen catabolism.
Cultured fibroblasts from patients with PD show changes
that might be associated with a necrosis-like cellular death
[13]. This change may be related to the intracellular accu-
mulation of the Gly-Pro dipeptides which could be respon-
sible for the typical skin lesions in PD, as well as for the
association with SLE caused by exposure to intracellular
protein. Ultrastructurally, collagen molecules have been
found to be shortened and to show non-homogeneous
packing of fibrils [14]. Thus it appears that the pathogen-
esis may involve angiopathy of small blood vessels,
probably due to disturbance of this connective tissue
metabolism, caused by deficiency of the prolidase en-
zyme [15]. Another mechanism that connects PD with
lupus might be through complement components such
as C1q, which has high proline content. Hypothetically,
PD may cause the synthesis of antigenically immunor-
eactive, but biologically defective, C1q, that alters im-
mune responses and thus predisposes to autoimmune
disease (9). This association between SLE and prolidase
deficiency has been reported previously in 7 cases (2 of
our cases patient number 2 and 3 were previously
briefly reported as part of a large series of PD patients)
[7-10,16]. The clinical features and laboratory findings
are presented in Table 1.
Most of the PD patients reported to have SLE present
relatively early in childhood, (average age 8.3 ± 4.6 years).
Table 1 Clinical and laboratory findings in SLE associated with prolidase deficiency




















Consanguinity + + + + ? ? unknown + + +




? ? Portugal Druze Arab Moslem Druze
Sex M F F M M F M F F M
Age of PD/SLE diagnosis 9m/8y 6m/3y /8y /12y ? /16y /25y 5/8 2y/2.5
Skin involvement + + + + + + + + + +
Maculo-papular rash + + + - + + - + + +
Vasculitis + - - - + - Necrotic lesion - - +
Leg ulcers - - + + + + + - - -
Splenomegaly + - + + - - + + + +
Splenectomy - - - - - + - -
CNS involvement - - - - - - - _ + _
seizure +
Renal disease + - - - - + + - + +
Kidney biopsy - - - Class III + Class IV Kidney
transplantation
Class IV
Renal failure - - - -
Hematological Disease + + + + - +
Anemia/Leukopenia/
thrombopenia
+ + + + - +
Recurrent infections + + + + - + + + -
Pulmonary disease + + + + - + + + -
ANA + + + - + + + + +
Positive ENA + + + + + + 1/640 + + +
Anti DNA + + + + + + - + + +
Hypocomplementemia + - - + + + + + + +
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PD and SLE are recurrent infections and variable skin
lesions. Leg ulcers were a predominant feature and
appeared in 5/10 patients. This clinical feature contrasts
with patients who have SLE without PD, in whom leg
ulcers are rarely reported. Lung disease among patients
with PD and SLE was found in 7/10 cases. Most of the
reported cases were bronchiectasis that may be due to
the recurrent infections. In one of our cases (no. 3), the
main lung disease was of cystic lung lesions combined
with ground glass appearance that may be due to PD
and less likely due to SLE. In contrast, clinical and sub-
clinical pleuropulmonary disease is a frequent manifest-
ation of childhood SLE. The most frequently reported
and described pleuropulmonary manifestations are pleural
effusion, pleuritis, acute and chronic pneumonitis, and
pulmonary hemorrhage [17-19]. Acute lupus pneumonitis
consisting of pulmonary infiltrates and atelectasis, occurs
in 10–15% of children with SLE. Chronic interstitial lung
disease has been reported in adults with SLE [17,20], but
not in children. Cystic lesions similar to the finding in the
imaging of patient no. 3 are not characteristic of SLE and
are more likely related to PD. Recently there have been a
few reports of patients with prolidase deficiency without
SLE who developed cystic lung lesion [21,22]. In reported
cases of PD patients that developed SLE, most patients
had some response to steroids and immunosuppressive
therapy; however skin lesions were usually unresponsive
to corticosteroid treatment. There were a few reports of
mortalities in these patients, most of them related to
infections [7-10].
Conclusions
There appears to be an association between prolidase
deficiency and SLE. Awareness of this observation may
be important in furthering our understanding of the
etiology of SLE. We recommend that an underlying
diagnosis of PD should be considered in some patients
with SLE, especially in patients who present with dys-
morphic features, developmental delay and poorly respon-
sive skin disease, as well as in patients who have SLE and
recurrent lung infections resembling cystic fibrosis. We
also believe that patients with an established diagnosis of
PD should be regularly monitored for an underlying auto-
immune disorder.
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